Symbio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited is involved in the development, manufacturing, and sales of pharmaceuticals and related operations in Japan and internationally. Its offerings include SyB V-1901, an antiviral drug for post-transplant infections, blood cancers, solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration marketed under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.